HERCULES, CA –October 17, 2012 –Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostics products, announces the release of Liquichek™ Whole Blood Immunosuppressant Control. This third party, human whole blood based product is designed for use as an assayed quality control material to monitor the precision of immunosuppressant drug testing procedures in the clinical laboratory. Its liquid formulation is suitable for use with immunoassay and chromatographic techniques.
This control can be used to monitor laboratory test procedures for some of the most common immunosuppressant drugs typically given to transplant patients to minimize organ rejection. These include Cyclosporine, Sirolimus, Tacrolimus, and Everolimus. Two convenient packaging configurations are available: a tri-level product and an additional higher level for most of the analytes.
Routine use of Liquichek Whole Blood Immunosuppressant Control provides laboratories the means to monitor the precision of their testing methods and is an aid to ensuring quality patient results on an ongoing basis.
The Unity™ Interlaboratory Program and the Unity Real Time™, an expert data management software solution designed to improve the effectiveness of quality control processes, are available for use with Liquichek Whole Blood Immunosuppressant Control.
For more information, please call 1-800-224-6723 or visit
www.biorad.com/tdmcontrols
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The company employs over 7,100 people globally and had revenues exceeding $2 billion in 2011. For more information, visit www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.
For more information contact:
Rochelle Stahl, Product Manager
Bio-Rad Laboratories, Inc.
949-598-1200
rochelle _stahl @bio-rad.com